12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Stivarga regorafenib regulatory update

EMA's CHMP issued a positive opinion recommending approval of Stivarga regorafenib from Bayer to treat metastatic colorectal cancer (mCRC) in adults who have been previously treated with or who are not considered candidates for available therapies, including fluoropyrimidine-based...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >